ArticleTranslational andrology and urology2025
A cross-sectional survey of experiences and outcomes of using testosterone replacement therapy in UK men.
Article in Translational andrology and urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Prevalence of late-onset testosterone deficiency (TD) ranges between 6-30% depending on diagnostic criteria. Recent data highlights various benefits of testosterone replacement therapy (TRT), including increased libido, mood, bone mineral density, and lean body mass. This study investigated the personal experiences of men with TD around low testosterone and TRT, including barriers to accessing TRT. Methods: Previous or current TRT users were recruited via email from private clinics' emailing lists, professional medical organisations and researchers' professional networks. Participants completed a 52-item structured questionnaire on Qualtrics XM, exploring their perceptions and experiences of TRT on their symptoms and quality of life. Associations between demographics, duration of symptoms and effectiveness were assessed using logistic regressions. Results: Among the 905 men on TD treatment, 86% delayed treatment for at least a year, including 24% who experienced symptoms for over 5 years before seeking care. Older men (aged 51+ years) were 1.61 times more likely to delay treatment. The majority (85%) reported TRT as effective or very effective, with longer-term users 2.6 times more likely to report TRT as very effective compared to recent starters. Primary motivations for seeking TRT included improving personal relationships (79%) and physical appearance (53%). Most (81%) relied on online sources for information; fewer (18%) felt comfortable discussing hormonal health with their peers. Patient expectations during medical consultations focused on diagnosis (77%), treatment options (64%) and learning about potential side effects (51%). The most common side effects were acne (24%), testicular shrinkage (24%) and nipple itchiness/gynaecomastia (19%). TRT users reported notable improvements in overall quality of life (75%), mental wellbeing (71%), self-esteem and self-confidence (69%) and appearance (61%). Conclusions: A significant proportion of men aged over 50 years surveyed reported experiencing prolonged symptoms of TD prior to seeking care. There is a need for greater awareness and education regarding TD symptoms, including streamlining timely and equitable access to effective treatment options.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.